Financials in USD. Standardized financial statements.
A compact view of how Aytu BioPharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $66.38M | $65.18M | $107.40M | $96.67M | $65.63M | $27.63M | $7.32M | $3.66M | $3.22M | $2.56M |
| Revenue Growth? | +1.8% | -39.3% | +11.1% | +47.3% | +137.5% | +277.5% | +100.0% | +13.6% | +25.7% | 0.0% |
| Cost of Revenue? | $20.55M | $16.13M | $40.77M | $46.39M | $36.43M | $8.28M | $2.20M | $2.05M | $1.42M | $957,076 |
| Gross Profit? | $45.83M | $49.05M | $66.63M | $50.28M | $29.20M | $19.35M | $5.12M | $1.61M | $1.80M | $1.61M |
| Gross Margin? | +69.0% | +75.3% | +62.0% | +52.0% | +44.5% | +70.0% | +69.9% | +44.0% | +56.0% | +62.6% |
| Operating Expenses? | $53.66M | $50.65M | $83.70M | $160.19M | $88.07M | $40.48M | $21.96M | $19.45M | $20.66M | $15.81M |
| Operating Income? | -$7.83M | -$1.59M | -$17.07M | -$109.91M | -$58.87M | -$21.13M | -$16.85M | -$19.70M | -$20.13M | -$21.70M |
| EBITDA? | -$4.67M | $1.41M | -$3.27M | -$27.96M | -$29.04M | -$12.21M | -$14.61M | -$15.25M | -$18.13M | -$21.81M |
| Income Before Tax | -$13.74M | -$10.38M | -$17.05M | -$108.89M | -$58.03M | -$13.62M | -$27.13M | -$10.19M | -$22.51M | -$28.18M |
| Income Tax Expense | $437,000 | $2.14M | $0 | -$110,000 | $259,000 | $0 | $20.04M | $0 | $0 | $0 |
| Net Income? | -$13.56M | -$15.84M | -$17.05M | -$108.78M | -$58.29M | -$13.62M | -$47.17M | -$10.19M | -$22.51M | -$28.18M |
| EPS? | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-69.60 | $-60.20 | $-1210.28 | $-3061.23 | $-193194.38 | $-1294738.36 |
| Diluted EPS? | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-69.60 | $-60.20 | $-1210.28 | $-3061.23 | $-193194.38 | $-1294738.36 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality